FNCH - Finch to get back rights to IBD product candidates after Takeda ends collaboration

• Finch Therapeutics Group ( NASDAQ: FNCH ) on Thursday said Japanese pharmaceutical major Takeda ( NYSE: TAK ) had ended their collaboration and that it would regain rights to investigational microbiome products FIN-524 and FIN-525.
• FNCH had signed a development and commercialization deal with TAK for FIN-524 and FIN-525 for the treatment of inflammatory bowel disease (IBD), which would now be terminated effective Nov. 17, Finch ( FNCH ) said in a statement .
• FNCH said it had got more than $44M from Takeda ( TAK ) over the course of the collaboration.
• Upon termination of the agreement, FNCH will get a royalty-free license to all data and intellectual property generated during the collaboration.
• FNCH stock -2.1% to $2.63 after hours.

For further details see: